financetom
Business
financetom
/
Business
/
Yes Bank gets binding bids from JC Flowers & Cerberus for its ARC
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Yes Bank gets binding bids from JC Flowers & Cerberus for its ARC
Feb 6, 2022 4:45 AM

Two private equity firms have submitted binding bids to acquire a stake in Yes Bank’s proposed asset reconstruction company (ARC), two people aware of the development told CNBC-TV18.

Share Market Live

NSE

US-based Cerberus Capital and JC Flowers & Company submitted binding bids, while the other shortlisted player's Oaktree Capital and Apollo Global Management stayed away, as per people in the know.

The deadline to submit binding bids for the ARC ended on Saturday, February 5.

CNBC-TV18 had earlier reported that four private equity players were shortlisted from a dozen Expressions of Interests (EOI) submitted for the ARC business, namely Cerberus Capital, JC Flowers and Company, Oaktree Capital, and Apollo Global Management.

Also read: Yes Bank ARC: Binding bids from private equity players likely by February 5

“We have to look at both financial and non-financial parts of the bid to make a decision,” said a person directly in the know, adding that the details of the bids submitted on Saturday are yet to be examined.

When asked if JC Flowers’s differences with its joint venture partner Eight Capital would affect the bid it made, this person said, “As far as the bank is concerned, JC Flowers has made the bid. Whether or not they come with their partner or rope in someone else in another matter.”

CNBC-TV18 reached out to Yes Bank for a comment, but no response was received at the time of publishing this story. Responses from Cerberus Capital, and JC Flowers and Co are also awaited.

“Out of the 15 EOIs (Expressions of Interest) we received, we expect many of the players like Edelweiss and SSG to participate in the auction process through the Swiss Challenge method to buy loans, even if they did not submit binding bids,” said one of the people quoted earlier.

Yes Bank had received EOIs from over a dozen players for its proposed ARC last year. Brookfield Asset Management, Ares SSG, Oaktree Capital Management, JC Flower, Vardhe Capital, CarVal Investors, Avenue Asia Group, Bain Capital’s India Resurgent Fund, Cerberus Capital, Apollo Global Management, Rohatyn Group and Silver Point Capital were among the players who had submitted EOIs. Four of these were subsequently shortlisted by the bank. Yes Bank has appointed Ernst & Young as the process adviser.

As per people in the know, Yes Bank will hold a 20 percent stake in the ARC, with the remaining stake to be held by the foreign partner. “We have 20 percent stake in mind for Yes Bank and remaining for partner, but the final structure will have to be as per RBI’s comfort,” said a person in the know.

The bank is looking to transfer over Rs 50,000 crores of loans to the ARC. The deal size expected to be around Rs 12,000-15,000 crores, CNBC-TV18 had reported.

Given the 15:85 deal structure of ARCs, where 15 percent is given in the form of cash and 85 percent in the form of security receipts, it will translate into the foreign partner bringing in about Rs 1450-1800 crores of cash for its 80 percent stake, CNBC-TV18 had reported

The bank, while inviting EOIs for its ARC earlier, had stipulated that an investor should have minimum assets under management and funds deployed globally of at least $ 5 billion.

This is the second attempt by Yes Bank to set up an ARC. The last time around, Reserve Bank of India had rejected its proposal to set up an ARC as it wasn’t keen on the bank being the majority shareholder due to potential conflicts of interest.

Even after the foreign partner is shortlisted, the bank will have to make a fresh application to RBI to seek its nod for the ARC license. The setting up of the company will ultimately depend on the regulator’s comfort with the proposed structure.

Yes Bank reported gross non-performing assets of Rs 28,654 crores, and Total Gross Restructured Loans of Rs 6,878 crores as of December 31, 2021. Its gross NPA ratio stood at 14.7 percent and net NPA ratio at 5.3 percent for the third quarter.

(Edited by : Pradeep Suresh V)

First Published:Feb 6, 2022 1:45 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Merck's RSV antibody for infants shows over 60% efficacy in mid-late-stage study
Merck's RSV antibody for infants shows over 60% efficacy in mid-late-stage study
Oct 17, 2024
Oct 17 (Reuters) - Merck ( MRK ) said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing respiratory syncytial virus (RSV) infections in infants. The seasonal shot met its primary goal in the mid-to-late stage trial, reducing the incidence of lower respiratory tract infections in healthy infants up to one year of age entering their...
US regional banks capitalize on rising deal fees to counter high deposit costs
US regional banks capitalize on rising deal fees to counter high deposit costs
Oct 17, 2024
(Reuters) - U.S. regional banks' profits outdid Wall Street expectations in the third quarter as their investment banking fees surged from a revival in dealmaking and helped offset higher deposit costs.  Underwriting and M&A activity picked up pace, taking advantage of a stock market rally and leaning on a combination of economic resilience and hopes of more cuts in interest...
US awards contracts for making higher enriched uranium for new reactors
US awards contracts for making higher enriched uranium for new reactors
Oct 17, 2024
WASHINGTON, Oct 17 (Reuters) - The U.S. rolled out initial contracts to four companies hoping to produce a new, more highly enriched uranium fuel for an expected wave of high-tech reactors, the U.S. Energy Department said on Thursday. Russia is currently the only country that makes the fuel called high-assay low-enriched uranium fuel, or HALEU, in commercial volumes. Funds to...
Supernus Pharmaceuticals Reports 'Promising' Data in Trial of Anti-Depression Drug Candidate
Supernus Pharmaceuticals Reports 'Promising' Data in Trial of Anti-Depression Drug Candidate
Oct 17, 2024
06:01 PM EDT, 10/17/2024 (MT Newswires) -- Supernus Pharmaceuticals ( SUPN ) said late Thursday the phase 2a open-label study of SPN-820 in adults with major depressive disorder yielded promising data. The company said the study evaluated the safety and tolerability of a 2400 mg dose of the investigational drug given once every three days as an adjunctive treatment to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved